Navigation Links
Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
Date:1/26/2012

istorical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Exalgo® is a registered trademark of Mallinckrodt LLC. CONTACTS:Investors: 

Patty Eisenhaur  

(862) 261-8141 

  Media: 

Charlie Mayr 

(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
(Date:4/22/2014)... Antipolis, 22 April 2014. The latest scientific advances and ... Heart Failure 2014, the main annual meeting of the ... Cardiology (ESC). Journalists will also hear breaking news on ... Acute Heart Failure, which is part of the main ... in Athens, Greece, at the Megaron Athens International Conference ...
(Date:4/22/2014)... technology, Berkeley Lab researchers have demonstrated the first ... to study the membranes of living cells. This ... can reveal information critical to whether a cell ... that can,t be obtained through conventional microscopy. , ... a physical means to both probe and manipulate ...
(Date:4/22/2014)... -- When mothers are exposed to trauma, illness, alcohol ... single molecular trigger in brain cells that can go ... disorder and some forms of autism. , Until now, ... impacted the cells of a developing brain. Past studies ... to alcohol or drug abuse or she experiences some ...
(Date:4/22/2014)... science fiction: In enemy territory, activate your cloaking device. ... invisible to the immune system. Now scientists at Harvard,s ... viral tactics to build the first DNA nanodevices that ... pave the way for smart DNA nanorobots that could ... than doctors can today; target drugs to tumors, or ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Life stressors trigger neurological disorders, researchers find 2Health News:Cloaked DNA nanodevices survive pilot mission 2Health News:Cloaked DNA nanodevices survive pilot mission 3
... cancerous lesions, researchers say , TUESDAY, Dec. 1 (HealthDay ... between cancerous and benign breast lesions, which reduces unnecessary ... of breast lesions that are biopsied turn out to ... "There,s a lot of room to improve specificity with ...
... Texas, Dec. 1 For many employers, the issue of ... employee benefit, it,s providing for the needs of their family ... with the help of Concentra, by opening a worksite health ... convenient health care services directly to employees and their dependents. ...
... , Gay Men,s Health Crisis Encourages ... , NEW YORK, Dec. 1 Today on World AIDS ... to continue helping diverse groups disproportionately affected by HIV and ... is announcing an innovative, interactive crystal methamphetamine resource, www.MyMethLife.org ...
... MRI , TUESDAY, Dec. 1 (HealthDay News) -- ... new study has found. , "What we have found is ... exposure. Distinct areas of the brain are affected differently," study ... Medical Center and a professor of radiology, pediatrics and neuroscience ...
... have gestational glucose intolerance (a condition less severe than ... as three months after birth, according to a new ... Journal of Clinical Endocrinology & Metabolism ( JCEM ... evaluate the relationship between gestational glucose intolerance and postpartum ...
... , LONDON, Dec. 1 ... market, particularly in the wireless assisted living devices segment. This segment ... growth is rising awareness levels among an ageing population about devices ... prefer to age at home - a trend supported by the ...
Cached Medicine News:Health News:Ultrasound With Elastography May Cut Down on Biopsies 2Health News:Hobby Lobby Selects Concentra to Open Health Center 2Health News:Hobby Lobby Selects Concentra to Open Health Center 3Health News:Nation's Oldest AIDS Organization Launches Innovative Tool to Reach New Faces of HIV on World AIDS Day 2Health News:Nation's Oldest AIDS Organization Launches Innovative Tool to Reach New Faces of HIV on World AIDS Day 3Health News:Childhood Lead Exposure Causes Permanent Damage: Study 2Health News:Glucose intolerance in pregnancy associated with postpartum cardiovascular risk 2Health News:Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe, Finds Frost & Sullivan 2Health News:Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe, Finds Frost & Sullivan 3
Continuous rocking motion graphic display....
Two sided, 72 frame, acrylic eyewear tower with side mirrors and sign holder on top. Breaks down for easy shipping....
... maximum impact for the marketing of optical ... displaying frames allows your retail area to ... and eye-catching displays. The products are shown ... motivated. Removable holders. Variable number of frames ...
A pre-assembled, hexagonal, revolving tower display with two round 19.75" in diameter adjustable shelves. Enjoy 3.5 square feet of elegant shelf space for your products....
Medicine Products: